Novo Nordisk and Pfizer’s bidding battle for Metsera escalates regardless of authorized threats

Novo Nordisk has raised its provide to purchase out weight problems biotech Metsera to $10bn as a bidding battle with Pfizer intensifies.

That is up from the $8.5bn that Novo provided final week when it submitted its preliminary, sudden, “unsolicited” provide. This provide shook the pharma sector after it appeared that Pfizer’s $7.3bn provide to take over Metsera was all however sure.

Beneath the newest proposal, Novo Nordisk would purchase all excellent shares of Metsera’s widespread inventory at a value of $62.20 per share in money, equal to an approximate aggregated fairness worth of $7.2bn.

The provide contains contingent worth rights (CVRs) for as much as $24.00 per share, an approximate aggregated worth of as much as $2.8bn primarily based on the achievement of sure medical and regulatory milestones. The brand new $10bn provide has been described as “superior” by Metsera’s board of administrators.

Pfizer refutes these claims, stating that Novo Nordisk’s provide “can’t qualify as superior” because the transaction is unlikely to be accomplished because of the “regulatory threat” related to it.

In the meantime, Novo Nordisk believes that the newest proposal, together with the construction of the transaction, complies with all relevant legal guidelines and highlights the corporate’s “dedication to investing within the US and curiosity in persevering with to develop the dimensions of its US investments”.

This up to date provide comes after Pfizer additionally upped its provide to $8.1bn to try to entice Metsera again.

In a Halloween scare, Pfizer launched a lawsuit towards each Metsera and Novo Nordisk on 31 October. The lawsuit, filed within the Delaware Court docket of Chancery, alleges that Novo Nordisk and Metsera breached the contractual merger settlement, claiming “breach of contract, breach of fiduciary obligation, and tortious interference”.

In the identical lawsuit, Pfizer had additionally requested the Delaware Court docket of Chancery to concern a brief restraining order to dam Metsera from terminating the Pfizer merger settlement and seeks all acceptable treatments to make sure the phrases of the merger settlement are totally enforced. This has been rejected by the courtroom, with one other listening to scheduled for five November.

Pfizer has since launched a second lawsuit towards the businesses, in addition to Metsera’s controlling shareholders, alleging Novo Nordisk’s provide violates Part 7 of the Clayton Act due to the anticompetitive results it will have within the US GLP-1RA sector.

Pfizer additionally claims that it constitutes an anticompetitive conspiracy between Novo Nordisk and Metsera in restraint of commerce in violation of Part 1 of the Sherman Act, and that it constitutes tried monopolisation and conspiracy to monopolise below Part 2 of the Sherman Act.

Lastly, it claims that Metsera’s controlling stockholders have conspired with Metsera and Novo Nordisk in furtherance of those anticompetitive actions.

Whoever emerges victorious from the bidding battle will declare Metsera’s vary of weight problems property, together with its month-to-month glucagon-like peptide-1 receptor agonist (GLP-1RA), MET-097i, which just lately posted weight lack of 14.1% in a Section IIb trial. The corporate additionally has an oral candidate MET-224o, which is in Section I trials.

It’s unsurprising that each Pfizer and Novo Nordisk are grappling to buy the biotech as GlobalData evaluation predicts the weight problems market to speed up in development, from $12.3bn in 2021, rising to $206.5bn in 2031 throughout the seven main markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

After Novo’s preliminary unsolicited bid, GlobalData senior analyst Shehroz Mahmood stated: “This aggressive bidding battle underscores the excessive strategic worth each firms place on Metsera’s ultra-long-acting GLP-1RA platform, notably MET-097i’s differentiated 380-hour half-life enabling month-to-month dosing comfort that would problem the weekly administration paradigm at the moment dominated by Novo’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide).

“The timing suggests Novo Nordisk recognises the specter of shedding market share to a rejuvenated Pfizer weight problems franchise and is prepared to pay a major premium to keep up its management place within the quickly increasing GLP-1RA weight problems market.”

GlobalData is the mother or father firm of Pharmaceutical Know-how.

“Novo Nordisk and Pfizer’s bidding battle for Metsera escalates regardless of authorized threats” was initially created and revealed by Pharmaceutical Know-how, a GlobalData owned model.

The knowledge on this website has been included in good religion for normal informational functions solely. It isn’t supposed to quantity to recommendation on which you need to rely, and we give no illustration, guarantee or assure, whether or not categorical or implied as to its accuracy or completeness. You will need to get hold of skilled or specialist recommendation earlier than taking, or refraining from, any motion on the idea of the content material on our website.